Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- Memorial Hermann Texas Medical Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Neuro-Oncology Associates — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- UT Health Houston Neurosciences - Texas Medical Center — Houston, Texas
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Texas: - Texas Oncology - Austin — Austin, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas - MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: …
Sponsor: Ivy Brain Tumor Center
NCT ID: NCT06388733
Sites in Texas: - Baylor Scott & White Health — Temple, Texas
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Texas: - The University of Texas — Houston, Texas
- University of Texas, MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Sponsor: Hoffmann-La Roche
NCT ID: NCT05503264
Sites in Texas: - University of Texas at Houston — Houston, Texas
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- University of Texas Houston Health Science Center — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of f…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03741673
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Texas: - Dell Children's Medical Center of Central Texas — Austin, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
- Medical City Dallas Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Cook Children's Medical Center — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Baylor Scott & White Medical Center — Temple, Texas
Phase 2 Recruiting NIH
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05859334
Sites in Texas: - UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Texas: - Dell Children's Blood and Cancer Center — Austin, Texas
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Texas: - The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center — Dallas, Texas
- Baylor College of Medicine — Houston, Texas
- Local Institution - 2104 — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Texas: - NEXT Dallas - Oncology Department — Irving, Texas
- START | San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Texas: - UT Southwestern — Dallas, Texas
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed …
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT02704858
Sites in Texas: - Baylor Scott & White Health — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Texas: - UT MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Texas: - Texas Children's Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Texas: - Research Site — Houston, Texas
- Research Site — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Texas: - University of Texas MD Anderson Cancer Center — Houston, Texas
- UT Health San Antonio University of Texas — San Antonio, Texas